Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

20.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Remarkably Stereospecific Utilization of ATP α,β-Halomethylene Analogues by Protein Kinases.

Journal of the American Chemical Society·2017
Same author

A Chemical-Genetic Approach to Generate Selective Covalent Inhibitors of Protein Kinases.

ACS chemical biology·2017
Same author

Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.

Journal of medicinal chemistry·2015
Same author

5'-β,γ-CHF-ATP diastereomers: synthesis and fluorine-mediated selective binding by c-Src protein kinase.

Organic letters·2015
Same author

Current status and challenge of Human Parasitology teaching in China.

Pathogens and global health·2012
Same author

Broadband focusing ultrasonic transducers based on dimpled LiNbO3 plate with inversion layer.

IEEE transactions on ultrasonics, ferroelectrics, and frequency control·2012

相关实验视频

Updated: Mar 17, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

开发针对受体氨酸激酶EphB3的特定,不可逆转的抑制剂

Alvin Kung, Ying-Chu Chen, Marianne Schimpl1

  • 1Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Building 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, United Kingdom.

Journal of the American Chemical Society
|August 2, 2016
PubMed
概括
此摘要是机器生成的。

研究人员开发了第一个针对EphB3受体氨酸激酶 (RTK) 的小分子抑制剂. 这些使用结构洞察力设计的向抑制剂使得详细研究EphB3在细胞生物学和疾病中的作用成为可能.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

相关实验视频

Last Updated: Mar 17, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

科学领域:

  • 生物化学
  • 分子生物学
  • 药理学

背景情况:

  • 人类肝细胞癌 (Eph) 受体氨酸激酶 (RTK) 是细胞迁移和增殖等过程的关键调节剂.
  • 由于该家族中的高同质性,开发特定于异形的小分子抑制剂具有挑战性.

研究的目的:

  • 开发首个针对单个Eph异型,EphB3的强效和特定小分子抑制剂.
  • 利用这些抑制剂来研究EphB3的生物功能和疾病贡献.

主要方法:

  • 结构生物信息分析以确定EphB3的独特特征.
  • 合成和特征的电友 quinazoline 抑制剂.
  • 在体外和细胞测定以评估抑制剂的效力和选择性.
  • 结晶学检查以确认抑制剂的结合和机制.
  • 用于全蛋白质组向研究的"可点击"抑制剂的开发.

主要成果:

  • 在EphB3激酶链区域中识别出一种独特的氨酸.
  • 在体外和细胞中强烈抑制EphB3的选择性电友基纳抑制剂的开发.
  • 证实了EphB3的共价抑制的晶结构.
  • 使用特定抑制剂证明EphB3的转自化.

结论:

  • 开发的抑制剂是针对EphB3的第一个强大和特定的工具.
  • 这些抑制剂对于剖析EphB3在生物过程和疾病中的特定作用是非常宝贵的.
  • 这项研究为开发异型选择性激酶抑制剂提供了一种新的策略.